Skip to main content

Table 2 Multivariable Cox proportional hazard model showing relative hazards (RH) for time-to-virologic-failure, fitted on the whole study population (n = 2,337)

From: A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

Factor

RH

95% CI

p-value

calendar year

before 2004 vs. 2007 and after

2.06

(1.67-2.54)

< 0.0001

 

2004 vs. after 2007 and after

1.62

(1.29-2.03)

< 0.0001

 

2005-2006 vs. 2007 and after

1.28

(1.06-1.55)

0.0109

cART

2NRTI+1PI vs. 2NRTI+1NNRTI

1.03

(0.83-1.27)

0.8028

 

2NRTI+1PI/r vs. 2NRTI+1NNRTI

0.63

(0.54-0.75)

< 0.0001

 

3NRTI vs. 2NRTI+1NNRTI

1.23

(0.92-1.64)

0.1599

age (per 10 years older)

0.89

(0.82-0.96)

0.0036

gender (male vs. female)

1.06

(0.91-1.23)

0.4668

mode of HIV-1 transmission

male homosexual vs. heterosexual

1.08

(0.88-1.33)

0.4680

 

IDU vs. heterosexual

1.08

(0.87-1.32)

0.4898

 

other/unknown vs. heterosexual

1.08

(0.9-1.29)

0.4248

nationality

non-Italian vs. Italian

1.23

(0.9-1.67)

0.1992

 

unknown vs. Italian

0.94

(0.78-1.14)

0.5475

HCV/HBV coinfection

unknown vs. no

1.18

(0.97-1.45)

0.1049

 

yes vs. no

1.04

(0.82-1.32)

0.7277

HIV-1 RNA per log10 copies/ml higher

1.27

(1.17-1.39)

< 0.0001

CD4+ count cells/mm3

< = 100 vs. > 500

1.57

(1.23-2)

0.0003

 

> 100 and < = 199 vs. > 500

1.16

(0.93-1.45)

0.1968

 

> 200 and < = 349 vs. > 500

1.22

(1-1.48)

0.0447

 

> 350 and < = 499 vs. > 500

0.98

(0.79-1.21)

0.8202

interval time from the first HIV-1 positive test to ART initiation

< = 12 vs. > 60 months

0.87

(0.67-1.13)

0.2944

 

> 12 and < = 60 vs. > 60 months

1.01

(0.81-1.27)

0.9114

 

unknown vs. > 60 months

0.92

(0.77-1.11)

0.3938

duration of prior ART exposures

< = 6 vs. > 24 months

0.84

(0.7-1.01)

0.0626

 

> 6 and < = 12 vs. > 24 months

0.92

(0.73-1.17)

0.5029

 

> 12 and < = 24 vs. > 24 months

0.83

(0.66-1.03)

0.0890

previous AIDS-defining events (yes vs. no)

0.86

(0.7-1.05)

0.1379

#previous ART switches

1.03

(1-1.05)

0.0522

previous ART class exposure

NRTI vs. ART-naïve

1.48

(1.01-2.17)

0.0441

 

NRTI and NNRTI vs. ART-naïve

1.38

(0.99-1.93)

0.0546

 

NRTI and NNRTI and PI vs. ART-naïve

1.43

(1.03-1.99)

0.0315

 

NRTI and NNRTI and PI/r vs. ART-naïve

2.96

(2.16-4.06)

< 0.0001

 

NRTI and PI vs. ART-naïve

2.18

(1.64-2.89)

< 0.0001

 

NRTI and PI/r vs. ART-naïve

2.72

(1.98-3.75)

< 0.0001

 

other classes vs. ART-naïve

2.31

(1.31-4.05)

0.0036

previous exposure to suboptimal ART (yes vs. no)

0.85

(0.71-1.03)

0.0946

viral subtype

02_AG vs. B

0.98

(0.61-1.57)

0.9402

 

C vs. B

1.41

(0.86-2.32)

0.1748

 

F1 vs. B

0.57

(0.3-1.06)

0.0750

 

other vs. B

1.26

(0.76-2.09)

0.3774

 

undetermined vs. B

1.12

(0.88-1.42)

0.3527

GSS*

ANRS per 1 point increase

0.72

(0.66-0.78)

< 0.0001

 

HIVdb per 1 point increase

0.68

(0.63-0.74)

< 0.0001

 

Rega per 1 point increase

0.71

(0.66-0.77)

< 0.0001

  1. RH: relative hazard; CI: confidence interval; cART: combination antiretroviral therapy; NRTI: nucleoside/nucleotide reverse transcriptase inhibitors; NNRTI: non-nucloeside reverse transcriptase inhibitors; PI: protease inhibitors; PI/r: ritonavir-boosted PI; IDU: injecting drug users; HCV: hepatitis C virus; HBV: hepatitis B virus; ART: antiretroviral therapy; GSS: genotypic susceptibility score; *fitted separately one from each other.
Back to article page

BMC Medical Informatics and Decision Making

ISSN: 1472-6947

Contact us